Related Experiment Video
Updated: Jun 27, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Molecular targets and targeted therapies in bladder cancer management
Ramy F Youssef1, Anirban P Mitra, Georg Bartsch
1Departments of Pathology, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA.
Abstract:
Bladder cancer remains a significant health problem. Currently, conventional histopathologic evaluation criteria (tumor grade and stage) are limited in their ability to accurately predict tumor behavior. A significant number of patients with muscle-invasive or extravesical disease treated by radical cystectomy alone die of metastasis. Intense research efforts are being made to better identify and categorize tumors by their molecular alterations and biological characteristics. A majority of the aggressive, invasive bladder carcinomas have alterations in the p53 and retinoblastoma pathways that regulate the cell cycle by interacting with signal transduction pathways. Angiogenesis further contributes to the neoplastic growth by providing a constant supply of oxygen and nutrients. It is becoming apparent that the accumulation of genetic and molecular changes ultimately determines a tumor's phenotype and subsequent clinical behavior. We provide a contemporary outline of our current understanding of the molecular and genetic events associated with tumorigenesis and progression. We emphasize the ways by which molecular biology is likely to affect the development of future therapies that will be able to target molecular alterations in individual tumors based on their respective profiles. The current status of targeted therapies for bladder cancer is also presented as well as the ongoing clinical trials.
Insights
Bladder cancer molecular changes, including p53 and retinoblastoma pathways, drive tumor growth and metastasis. Understanding these alterations is key to developing targeted therapies for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Bladder cancer poses a significant health challenge with limitations in current histopathologic grading for predicting tumor behavior.
- Muscle-invasive or extravesical bladder cancer often leads to metastasis despite radical cystectomy.
- There is a critical need for improved methods to categorize tumors based on molecular and biological characteristics.
Purpose of the Study:
- To outline the current understanding of molecular and genetic events in bladder cancer tumorigenesis and progression.
- To highlight the role of molecular biology in developing future targeted therapies.
- To present the current status of targeted therapies and ongoing clinical trials for bladder cancer.
Main Methods:
- Review of current literature on molecular alterations in bladder cancer.
- Analysis of genetic pathways (p53, retinoblastoma) involved in cell cycle regulation.
- Examination of the role of angiogenesis in tumor growth.
Main Results:
- Aggressive bladder carcinomas frequently exhibit alterations in the p53 and retinoblastoma pathways.
- Angiogenesis plays a crucial role in neoplastic growth by supplying nutrients and oxygen.
- Accumulated genetic and molecular changes determine tumor phenotype and clinical behavior.
Conclusions:
- Molecular profiling of individual tumors is essential for developing personalized, targeted therapies.
- Future bladder cancer treatments will likely focus on targeting specific molecular alterations.
- Understanding the molecular basis of bladder cancer is critical for advancing treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase